18F-αvβ6-Binding-Peptide

N/A

Report date: 2025/11/21 17:15:39
NME

Base Information

Drug Name18F-αvβ6-Binding-Peptide
Drug Alias Name18F-αvβ6-BP
ClassificationDiagnostic agent (In vivo) > Radionuclide Imaging agentRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Fluorine > 18F +[5] 
Mechanisms of ActionPositron-emission tomography enhancersIntegrin alpha-V/beta-6 antagonists
TargetsIntegrin alpha-V/beta-6
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Metastatic breast cancerLung Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer InstituteNational Institutes Of Health
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of California DavisNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Metastatic breast cancerLung Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A